LivingGLP1
parallel randomized trial

S003077

Design

Randomized
30
Start year
Treatment
1.43 weeks, follow-up 1.86 weeks
Countries
United Kingdom (1 sites)
Sponsor
(not reported)
Eligibility
healthy men aged 18 to 45, BMI 19 to 30

Conduct and analysis

Blinding
double blind
Sequence generation
not reported
Allocation concealment
not reported
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
per protocol
Missing data

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1liraglutide (NN2211)
NN2211 1.25 ug/kg
lifestyle: none1
A2liraglutide (NN2211)
NN2211 5.0 ug/kg
lifestyle: none2
A3liraglutide (NN2211)
NN2211 7.5 ug/kg
lifestyle: none4
A4liraglutide (NN2211)
NN2211 10 ug/kg
lifestyle: none4
A5liraglutide (NN2211)
NN2211 12.5 ug/kg
lifestyle: none4
A6Placebo
Placebo
lifestyle: none10

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.
CharacteristicStatisticNN2211 1.25 ug/kg
A1
NN2211 5.0 ug/kg
A2
NN2211 7.5 ug/kg
A3
NN2211 10 ug/kg
A4
NN2211 12.5 ug/kg
A5
Placebo
A6
Whole trial
ALL
other malen30

Results

37 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
Serious adverse events (6 lines; O25)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 1not stated; modified itt; R0027243:Results
A2events0 / 2not stated; modified itt; R0027243:Results
A3events0 / 4not stated; modified itt; R0027243:Results
A4events0 / 4not stated; modified itt; R0027243:Results
A5events0 / 4not stated; modified itt; R0027243:Results
A6events0 / 10not stated; modified itt; R0027243:Results
Discontinuation due to adverse events (6 lines; O26)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events1 / 1not stated; modified itt; R0027243:Results
A2events0 / 2not stated; modified itt; R0027243:Results
A3events1 / 4not stated; modified itt; R0027243:Results
A4events1 / 4not stated; modified itt; R0027243:Results
A5events0 / 4not stated; modified itt; R0027243:Results
A6events0 / 10not stated; modified itt; R0027243:Results
Nausea (6 lines; O27A)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 1not stated; modified itt; R0027243:Table 1
A2events0 / 2not stated; modified itt; R0027243:Table 1
A3events1 / 4not stated; modified itt; R0027243:Table 1
A4events3 / 4not stated; modified itt; R0027243:Table 1
A5events0 / 4not stated; modified itt; R0027243:Table 1
A6events1 / 10not stated; modified itt; R0027243:Table 1
Vomiting (6 lines; O27B)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 1not stated; modified itt; R0027243:Table 1
A2events0 / 2not stated; modified itt; R0027243:Table 1
A3events1 / 4not stated; modified itt; R0027243:Table 1
A4events0 / 4not stated; modified itt; R0027243:Table 1
A5events0 / 4not stated; modified itt; R0027243:Table 1
A6events0 / 10not stated; modified itt; R0027243:Table 1
Diarrhea (6 lines; O27C)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 1not stated; modified itt; R0027243:Table 1
A2events0 / 2not stated; modified itt; R0027243:Table 1
A3events0 / 4not stated; modified itt; R0027243:Table 1
A4events1 / 4not stated; modified itt; R0027243:Table 1
A5events1 / 4not stated; modified itt; R0027243:Table 1
A6events0 / 10not stated; modified itt; R0027243:Table 1
Constipation (6 lines; O27D)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 1not stated; modified itt; R0027243:Table 1
A2events0 / 2not stated; modified itt; R0027243:Table 1
A3events0 / 4not stated; modified itt; R0027243:Table 1
A4events0 / 4not stated; modified itt; R0027243:Table 1
A5events0 / 4not stated; modified itt; R0027243:Table 1
A6events1 / 10not stated; modified itt; R0027243:Table 1
Discontinuation due to gastrointestinal adverse events (1 lines; O27E)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A4events1 / 4not stated; modified itt; R0027243:Results